Interferon alpha as adjuvant postsurgical treatment of melanoma: A meta-analysis

Dermatology

Volumn 208, Issue 1, 2004, Pages 43-48

  Pirard, Delphine ^a   Heenen, Michel ^a   Melot, Christian ^a   Vereecken, Pierre ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Interferon; Adjuvant treatment; Melanoma; Meta analysis, interferon treatment

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DATA BASE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; MEDLINE; MELANOMA; META ANALYSIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; HUMANS; INTERFERON-ALPHA; MELANOMA; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0942300677     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075045     Document Type: Article

References (28)

1. Rigel DS, Carucci JA: Malignant melanoma: Prevention, early detection and treatment in the 21st century. CA Cancer J Clin 2000;50:215-236.
2. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996;14:7-17.
3. Grob JJ, Deno B, De la Salmonière P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, Lok C, Chastang C, Bonerandi JJ: Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastasis. Lancet 1998;351:109-110.
4. Kleeberg U, Bröcker EB, Lejeune F, Chartier C, Egger C, Marsden J, Ruiter D, Suciu S: Adjuvant trial in melanoma patients comparing rIFN-α to IFN-γ to Iscador to a control group after curative resection of high risk primary (>3 mm) or regional lymph node metastasis (EORTC 18871) (abstract 264). Eur J Cancer 1999;suppl 4:S82.
5. Krajsova I, Kysela T, Horazdovsky J, Kohoutek M: High risk cutaneous melanoma: Impact of the adjuvant interferon alpha 2 treatment (abstract 2901). ASCO, San Francisco, 2001.
6. Hancock BW, Wheatley K, Harrison G, Gorc M: Aim high - Adjuvant interferon in melanoma (high risk), a United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) randomised study of observation versus adjuvant low dose extended duration interferon alpha-2a in high risk resected malignant melanoma (abstract 1393). ASCO, San Francisco, 2001.
7. Cucherat M: Méta-analyse des essais thérapeutiques. Paris, Masson, 1997, pp 149-203.
8. Kirkwood JM, Ibrahim JG, Sondak VK, et al: High-and-low dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-2458.
9. Rusciani L, Petraglia S, Alotto M, Calvieri S, Vezzoni G: Postsurgical adjuvant therapy for melanoma. Cancer 1997;79:2354-2360.
10. Creagan ET, Dalton RJ, Ahmann DL, et al: Randomised, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776-2783.
11. Pehamberger H, Soyer PH, Steiner A, et al: Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 1998;16:1425-1429.
12. Cameron DA, Cornbleet MC, Mackie RM, et al: Adjuvant interferon alpha 2-b in high risk melanoma - The Scottish study. Br J Cancer 2001;84:1146-1149.
13. Kokoschka E-M, Trautinger F, Knobler RM, Pohl-Markl H, Micksche M: Long-term adjuvant therapy of high risk malignant melanoma with interferon α2b. J Invest Dermatol 1990;95:193S-197S.
14. Cascinelli N, Belli F, Mackie RM, Santinami M, Bufalino R, Morabito A: Effect of long term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet 2001;358:866-869.
15. Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ: Economic analysis of adjuvant interferon alfa-2b in high risk melanoma based on projections from eastern cooperative oncology group 1684. J Clin Oncol 1997;15:2351-2358.
16. Saiag P: Interféron à hautes doses et traitement adjuvant du mélanome de mauvais pronostic: requiem pour une AMM? Ann Dermatol Vénéréol 1999;126:211-213.
17. Kimyai-Asadi A, Usman A: The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: The need for more evidence. J Am Acad Dermatol 2000;43:708-711.
18. Essner R: The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma. Semin Oncol 1997;24(suppl 4):S8-S10.
19. Balch CM, Buzaïd A, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
20. Lens MB, Dawes M: Interferon alfa therapy for malignant melanoma: A systematic review of randomised controlled trials. J Clin Oncol 2002;20:1818-1825.
21. Wheatley K, Hancock B, Gore M, Suciu S, Eggermont A: Interferon-α as adjuvant therapy for melanoma: A meta-analysis of the randomised trials (abstract 1394). ASCO, San Francisco, 2001.
22. Kanzler MH, Swetter SM: Malignant melanoma. J Am Acad Dermatol 2003;48:780-783.
23. Sondak VK: Use of adjuvant therapy in cutaneous melanoma. Expert Rev Anticancer Ther 2001;1:421-426.
24. Dummer R, Bosch U, Panizzon R, Bloch PH, Burg G: Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2001;203:75-80.
25. Roberts DL, Anstey AV, Bartow RJ, Cox NH, Newton Bishop JA, Corrie PG, Evans J, Gire ME, Hall PN, Kirkham N: UK guidelines for the management of cutaneous melanoma. Br J Dermatol. 2002;146:7-17.
26. Brochez L, Verhaeghe E, Sales F, Del Marmol V, Deraemaecker R, Vossaert K, Naeyaert JM: Current guidelines in melanoma treatment. Melanoma Working Group of Gent and Bordet. Dermatology 2000;200:160-166.
27. Kroon BB, Bergman W, Coebergh JW, Ruiter DJ: Consensus on the management of malignant melanoma of the skin in the Netherlands. Melanoma Res 1999;9:207-212.
28. Negries S, Fervers B, Bailly C, Beckendorf V, Cupissol D, Dore JF, Dorval T, Garbay JR, Vilmer C: Standards, options and recommendations (SOR): Clinical practice guidelines for diagnosis, treatment and follow-up of cutaneous melanoma. Bull Cancer 2000;87:173-182.